Harmony Biosciences Holdings, Inc. (HRMY) Q1 2026 Earnings Call Transcript
Harmony Biosciences Holdings, Inc. (HRMY) Q1 2026 Earnings Call Transcript
HRMY - Harmony Biosciences Holdings, Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$46.80
DETAILS
HIGH:
$62.00
LOW:
$31.00
MEDIAN:
$46.00
CONSENSUS:
$46.80
UPSIDE:
55.22%
Stock News
Harmony Biosciences Holdings, Inc. (HRMY) Q1 Earnings and Revenues Miss Estimates
Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.55 per share, missing the Zacks Consensus Estimate of $0.76 per share. This compares to earnings of $0.78 per share a year ago.
Harmony Biosciences Reports Q1 Financial Results and Confirms 2026 Net Revenue Guidance of Over $1 Billion; Reinforces 2026 Strategic Priorities
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today reported Q1 2026 revenue of $215.4 million, delivering 17% year‑over‑year growth for WAKIX®. Performance during the quarter reflected continued strong demand, offset by market access headwinds observed every Q1, which were more pronounced this year. This follows the strongest three consecutive quarters in franchise history, and the Company reinforced 2026 full year revenue guidance. The Company also.
Looking for a Growth Stock? 3 Reasons Why Harmony Biosciences (HRMY) is a Solid Choice
Harmony Biosciences (HRMY) is well positioned to outperform the market, as it exhibits above-average growth in financials.
HRMY or ARGX: Which Is the Better Value Stock Right Now?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Harmony Biosciences Holdings, Inc. (HRMY) or argenex SE (ARGX). But which of these two stocks is more attractive to value investors?
Wall Street Analysts Think Harmony Biosciences (HRMY) Could Surge 34.81%: Read This Before Placing a Bet
The mean of analysts' price targets for Harmony Biosciences (HRMY) points to a 34.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Harmony Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026, before the open of the U.S. financial markets. Harmony will host a conference call and webcast on May 7, 2026, at 8:30 a.m. ET to discuss the results. To participate in the call, please dial 800-274-8461 (domestic) or 203-518-9814 (international or alternate), and reference passcode HRMYQ126. It is recommende.
Harmony Biosciences to Present Open-Label Extension Data From Phase 3 ARGUS Trial at the 2026 American Academy of Neurology Annual Meeting
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that it will present encore open-label extension data from the company's investigation of EPX-100 (clemizole hydrochloride) in the ongoing Phase 3 ARGUS trial for the treatment of Dravet syndrome at the 2026 American Academy of Neurology Annual Meeting being held April 18 – 22 in Chicago, IL. The ARGUS trial is currently enrolling, and more information about the trial can be found at argust.
Harmony Biosciences Eyes $1B WAKIX Runway, Teases 2026 Pipeline Catalysts at Needham Conference
Harmony Biosciences (NASDAQ: HRMY) executives outlined 2026 priorities at Needham and Company's Virtual Healthcare Conference, emphasizing continued growth for WAKIX and multiple late-stage pipeline readouts across sleep-wake and rare epilepsy indications. WAKIX outlook and commercial execution President and CEO Jeffrey Dayno said Harmony is "on track to achieve over $1 billion in net revenue for WAKIX
Harmony Biosciences Holdings, Inc. (HRMY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Harmony Biosciences Holdings, Inc. (HRMY) Presents at 25th Annual Needham Virtual Healthcare Conference Transcript
Harmony Biosciences Appoints Glenn Reicin as Chief Financial Officer
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced the appointment of Glenn Reicin as Chief Financial Officer, effective immediately, supporting Harmony's continued focus on strategic growth, financial strength, and long‑term value creation. Harmony is also reiterating its 2026 net product revenue guidance of $1.0 to $1.04 billion. Mr. Reicin is a seasoned biopharmaceutical executive with extensive experience across publicly traded and pri.
Harmony Biosciences Strengthens Executive Team With New Appointment and Announces Additions to Its Board
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced the appointment of Peter Anastasiou as Chief Operating Officer and updates to its Board of Directors, including the appointment of Troy Ignelzi as a director and the nomination of Geno J. Germano as a director for election at Harmony's 2026 Annual Meeting of Shareholders. Mr. Anastasiou previously served on Harmony Biosciences' Board of Directors, where he contributed strategic insight acro.
Harmony Biosciences to Participate in 25th Annual Needham Virtual Healthcare Conference
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced that Harmony's management team will participate in a fireside chat at the upcoming 25th Annual Needham Virtual Healthcare Conference on Monday, April 13, 2026, at 9:30 a.m. ET. A webcast of the fireside chat will be available on the investor page of the Harmony Biosciences website at https://ir.harmonybiosciences.com/. About Harmony Biosciences Harmony Biosciences is a pharmaceutical compan.
Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Receives Average Recommendation of “Hold” from Brokerages
Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY - Get Free Report) has received an average rating of "Hold" from the twelve analysts that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, six have issued a hold rating, four have given a buy rating and one has
Harmony Biosciences to Participate in Upcoming Investor Conferences
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today announced that Harmony's management team will attend the following upcoming investor conferences. Leerink Partners Global Healthcare Conference Date: March 9, 2026 Location: Miami, FL UBS Biotech Summit Date: March 9, 2026 Location: Miami, FL Barclays 28th Annual Global Healthcare Conference Date: March 10, 2026 Location: Miami, FL About Harmony Biosciences Harmony Biosciences is a pharmaceutical co.
Harmony Biosciences Holdings, Inc. (HRMY) Q4 2025 Earnings Call Transcript
Harmony Biosciences Holdings, Inc. (HRMY) Q4 2025 Earnings Call Transcript
Harmony Biosciences Holdings, Inc. (HRMY) Q4 Earnings Miss Estimates
Harmony Biosciences Holdings, Inc. (HRMY) came out with quarterly earnings of $0.38 per share, missing the Zacks Consensus Estimate of $0.84 per share. This compares to earnings of $0.85 per share a year ago.
Harmony Biosciences Reports Strong 2025 Financial Results and Reiterates 2026 Net Revenue Guidance of Over $1 Billion
PLYMOUTH MEETING, Pa.--(BUSINESS WIRE)--Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY) today announced earnings with reported revenue of $243.8 million for Q4 2025, representing 21% year-over-year revenue growth for WAKIX®. For the full year 2025, the company generated $868.5 million in net product revenue, reflecting continued commercial strength as evidenced by six consecutive years of revenue growth and profitability. The company enters the year with significant momentum, reinforcing its.
4 Value Stocks to Buy Now Amid AI-Driven Market Volatility
Value stocks are back in focus as markets remain steady. HRMY, TRIP, AES and CNXC screen cheap on P/CF, offering growth and cash flow strength.
Top 5 Bargain P/B Stocks Investors Should Watch Now
AES joins four other low P/B stocks that screen for value, growth and liquidity, offering investors undervalued picks to watch in February.
Price Targets
Harmony Biosciences downgraded to Hold from Buy at Deutsche Bank
$31.00
(was $29.16)
Deutsche Bank
Harmony Biosciences price target raised to $50 from $46 at Mizuho
$50.00
(was $35.28)
Mizuho Securities
Harmony Biosciences assumed at Neutral from Buy at UBS
$46.00
(was $37.93)
Youn Shim
·
UBS
Harmony Biosciences price target lowered to $45 from $48 at Truist
$45.00
(was $37.55)
Truist Financial
Harmony Biosciences price target raised to $46 from $39 at Mizuho
$46.00
(was $35.29)
Mizuho Securities
Oppenheimer Reiterates Outperform Rating on Harmony Biosciences Holdings Inc. (HRMY) Post Mgmt Meet
$62.00
(was $34.31)
Andreas Argyrides
·
Oppenheimer
Harmony Biosciences price target raised to $36 from $35 at Mizuho
$36.00
(was $29.64)
Mizuho Securities
Harmony Biosciences price target lowered to $43 from $50 at UBS
$43.00
(was $26.84)
UBS
Harmony Biosciences price target lowered to $55 from $70 at H.C. Wainwright
$55.00
(was $27.04)
H.C. Wainwright
Harmony Biosciences resumed with a Neutral at Goldman Sachs
$33.00
(was $34.33)
Corinne Johnson
·
Goldman Sachs
Harmony Biosciences price target lowered to $48 from $55 at UBS
$48.00
(was $29.36)
UBS
Goldman Sachs Reiterates Sell Rating on Harmony Biosciences Holdings Inc. (HRMY)
$28.00
(was $41.49)
Corinne Jenkins
·
Goldman Sachs
Harmony Biosciences price target raised to $52 from $42 at Mizuho
$52.00
(was $33.60)
Graig Suvannavejh
·
Mizuho Securities
UBS starts Harmony Biosciences with Buy on Wakix growth
$56.00
(was $36.89)
Ashwani Verma
·
UBS
Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $42 at Mizuho
$42.00
(was $33.55)
Graig Suvannavejh
·
Mizuho Securities
Oppenheimer on Harmony Biosciences Holdings Inc. (HRMY): 'WAKIX Approved for EDS in Pediatric Narcolepsy, Small But Meaningful Commercial Opportunity'
$56.00
(was $30.39)
Francois Brisebois
·
Oppenheimer
Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $52 at Needham
$52.00
(was $30.37)
Ami Fadia
·
Needham
Harmony Biosciences Holdings Inc. (HRMY) PT Raised to $37 at Raymond James
$37.00
(was $30.91)
Danielle Brill
·
Raymond James
Harmony Biosciences upgraded to Buy from Hold at Jefferies
$61.00
(was $47.63)
Chris Howerton
·
Jefferies